

Delta variants of SARS-CoV-2 cause significantly increased vaccine breakthrough COVID-19 cases in Houston, Texas

James M. Musser, MD, PhD¹; Paul A. Christensen, MD¹; Randall J. Olsen, MD, PhD¹; S. Wesley Long, MD, PhD¹; Sishir Subedi, MS¹; James J. Davis, PhD²; Parsa Hodjat, MD¹; Debbie R. Walley MD¹; Jacob C. Kinskey, MD¹; Jimmy Gollihar PhD³

¹Center for Infectious Diseases, Houston Methodist Research Institute and Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas

²Computing, Environment and Life Sciences, Argonne National Laboratory, Lemont, Illinois

³CCDC Army Research Laboratory-South, Austin, Texas

Corresponding Author: James M. Musser, MD, PhD, Department of Pathology and Genomic Medicine, Houston Methodist Hospital and Houston Methodist Research Institute, Houston, TX 77030 (jimmusser@houstonmethodist.org).

Manuscript Word Count: 803

Delta variants (B.1.617.2, AY.2, and AY.3) have become the focus of intense international concern because they are causing widespread COVID-19 disease in Southeast Asia, Europe, the United States, and elsewhere (<https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html>, last accessed: July 19, 2021; <https://www.gov.uk/government/collections/new-sars-cov-2-variant>, last accessed: July 19, 2021). For example, Delta has rapidly replaced the Alpha variant in the United Kingdom, previously the cause of virtually all COVID-19 cases in that country (<https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---13-july-2021>, last accessed July 19, 2021; <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurvey/pilot/9july2021>, last accessed July 19, 2021). Vaccine breakthrough cases caused by SARS-CoV-2 variants also have become of considerable public health and biomedical interest worldwide¹⁻⁴. To study Delta and vaccine breakthrough cases in metropolitan Houston, we sequenced the genomes of 3,913 SARS-CoV-2 from patient samples acquired March 15, 2021 through July 3, 2021 using an Illumina NovaSeq 6000 instrument⁵. This period encompasses the time from initial identification of a Delta-related variant in our large Houston Methodist healthcare system until Delta variants became the majority (>58%) of all new cases. The sample is 91% of the 4,281 cases of COVID-19 diagnosed in our health system during this period. Delta variants were identified based on genome sequence data as designated by Pangolin (<https://cov-lineages.org/resources/pangolin.html>, last accessed July 19, 2021). During the study period 213 patients were diagnosed with Delta variants, and 255 of the 3,913 patients (6.5%) met the CDC definition of vaccine breakthrough cases (Table 1A)

(<https://www.cdc.gov/vaccines/covid-19/health-departments/breakthrough-cases.html>, last accessed July 19, 2021). Breakthrough cases received either the Pfizer-BioNTech BNT162b2 (n = 213, 84%), Moderna mRNA-1273 (n = 34, 13%), or J&J/Janssen JNJ-78436735 (n = 5, 2%) vaccines, generally reflecting the supermajority of BNT162b2 vaccinations in our health system; vaccine type was not specified for three individuals. Three patients with Delta Plus (Delta plus the K417N spike amino acid substitution) were identified, all diagnosed in July. Consistent with extensive infections caused by Delta variants in Southeast Asia and elsewhere, several patients had very recent travel histories to countries with a high prevalence of these variants, suggesting acquisition abroad and importation into Houston. Patients with Delta variants were identified in 95 zip codes throughout the metropolitan area. A total of 69 Delta subvariants was identified, likely reflecting the large population sizes and genetic diversity of Delta globally and multiple introductions into the Houston area. Patients infected with the same subvariant usually lived in different zip codes and had no apparent epidemiological link, consistent with the ability of Delta to spread very rapidly.

There is a considerable lack of detailed information about patients in the United States with COVID-19 caused by Delta variants

(<https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---13-july-2021>, last accessed July 19, 2021). Compared to all other patients, there was no significant difference in median age, gender, admission rate, disease severity or hospital length of stay (Table 1A). However, Delta cases were significantly more likely to be Asian (supporting multiple recent entry points) and less likely to be Hispanic or Latino, have significantly lower PCR cycle threshold (Ct) values (a proxy for higher virus

load, a finding consistent with the reported increased transmissibility of Delta variants) on initial diagnosis, and cause a significantly higher rate of vaccine breakthrough cases (19.7% compared to 5.8% for all other variants) (Table 1A).

We next examined metadata for the 255 vaccine breakthrough cases (Table 1B). Vaccinated patients had a significantly higher Ct, likely indicating lower virus load on initial diagnosis. A greater percentage of patients with Delta breakthrough cases was admitted to the hospital, but the number did not reach significance (Table 1B).

Our genome sequence data document a very rapid increase of Delta variant cases in metropolitan Houston and a considerable corresponding decrease of COVID-19 cases caused by Alpha, findings similar to epidemiologic trends observed in the UK. Delta was significantly more likely to cause a vaccine breakthrough case (Table 1A). However, importantly, only 6.5% of all COVID-19 cases occurred in fully immunized individuals, and relatively few of these patients required hospitalization. In the aggregate, our data add critical new information to the finding that these three vaccines are highly efficacious in decreasing severe COVID-19 disease, hospitalizations, and deaths.

Author Contributions: Drs. Musser, Christensen, Olsen, and Long had full access to all study data and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Musser, Christensen, Olsen, Long

Data acquisition, analysis, or interpretation of data: All authors

Drafting of the manuscript: All authors

Statistical analysis: Christensen

Obtained funding: Musser and Davis

Supervision: Musser

Authorship: Musser, Christensen, Olsen, and Long contributed equally and are co-first authors

Conflict of Interest Disclosures: The authors report no conflict of interest.

Institutional Review Board statement: This work was approved by the Houston Methodist Research institutional review board (IRB1010-0199).

Funding/Support: The research was supported by the Houston Methodist Academic Institute Infectious Diseases Fund and many generous Houston philanthropists. James Davis was funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93019C00076.

Role of Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Disclaimer: The findings and conclusions in this article are those of the authors and do not necessarily reflect the views of the U.S. Army.

Additional Contributions: We are indebted to Drs. Marc Boom and Dirk Sostman for their ongoing support. We thank Matthew Ojeda Saavedra, Prasanti Yerramilli, Layne Pruitt, Kristina Reppond, Madison N. Shyer, Jessica Cambric, Ryan Gadd, Rashi M. Thakur, Akanksha Batajoo, Regan E. Mangham, Sindy J. Pena, and Trina Trinh for technical support. We acknowledge the assistance of Robert Olson, Maulik Shukla and Marcus Nguyen at the Bacterial and Viral Bioinformatics Resource Center for their assistance with sequence analysis. All consensus genomes have been deposited in GISAID's EpiCoV Database (www.gisaid.org). We thank Drs. Sasha Pejerrey and Kathryn Stockbauer for editorial contributions.

Additional Information: Genome data used in this study have been deposited to GISAID.

References

1. Hacısuleyman E, Hale C, Saito Y, et al. Vaccine Breakthrough Infections with SARS-CoV-2 Variants. *N Engl J Med* 2021;384:2212-8.
2. Brosh-Nissimov T, Orenbuch-Harroch E, Chowers M, et al. BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully-vaccinated hospitalized COVID-19 patients in Israel. *Clin Microbiol Infect* 2021.
3. COVID-19 Vaccine Breakthrough Infections Reported to CDC - United States, January 1-April 30, 2021. *MMWR Morb Mortal Wkly Rep* 2021;70:792-3.
4. Kustin T, Harel N, Finkel U, et al. Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. *Nat Med* 2021.
5. Olsen RJ, Christensen PA, Long SW, et al. Trajectory of Growth of SARS-CoV-2 Variants in Houston, Texas, January through May 2021 Based on 12,476 Genome Sequences. *Am J Pathol* 2021 (in press).

Table 1A. Summary of pertinent patient metadata for the 3,913 unique patients

	Delta Variant	Other Variants	Total	Statistical Analysis
No. (%) with data	213 (5.4%)	3700 (94.6%)	3913	
Patient Characteristics				
Median Age (Years)	47.5	48.2	48.1	$P=0.9430$ Mann-Whitney
Female	103 (48.4%)	1923 (52.0%)	2026 (51.8%)	$P=0.3238$ Fisher's exact test
Male	110 (51.6%)	1777 (48.0%)	1887 (48.2%)	
Ethnicity				
Caucasian	98 (46.2%)	1448 (39.4%)	1546 (39.8%)	$P<0.0001$ Chi-square
Hispanic or Latino	35 (16.5%)	1125 (30.6%)	1160 (29.9%)	
Black	56 (26.4%)	862 (23.5%)	918 (23.6%)	
Asian	14 (6.6%)	108 (2.9%)	122 (3.1%)	
Native American	2 (0.9%)	15 (0.4%)	17 (0.4%)	
Hawaiian/Pacific Islander	2 (0.9%)	4 (0.1%)	6 (0.2%)	
Unavailable	5 (2.4%)	111 (3.0%)	116 (3.0%)	
BMI				
Median BMI	28.8	30.3	30.2	$P=0.0266$ Mann-Whitney
Admission Data				
Admitted	107 (50.2%)	2022 (54.6%)	2129 (54.4%)	$P=0.2291$ Fisher's exact test Odds Ratio: 0.838 (95% CI 0.633 to 1.109)
Not Admitted	106 (49.8%)	1678 (45.4%)	1784 (45.6%)	
Median LOS (Days)	5.9	5.0	5.0	$P=0.066$ Mann-Whitney
Max Respiratory Support				
Mechanical Ventilation/ECMO	9 (8.4%)	167 (8.3%)	176 (8.3%)	$P=0.6430$ Chi-square

Supplemental Oxygen	77 (72.0%)	1391 (68.8%)	1468 (69.0%)	
Room Air	21 (19.6%)	464 (22.9%)	485 (22.8%)	
Mortality				
Alive	208 (97.7%)	3553 (96.0%)	3761 (96.1%)	$P=0.2769$
Deceased	5 (2.3%)	147 (4.0%)	152 (3.9%)	Fisher's exact test
				Odds Ratio: 0.581 (95% CI 0.252 to 1.361)
Median PCR Cycle Threshold				
Abbott Alinity	21.475 n = 80	25.92 n = 1340	n = 1420	$P=0.0006$ Mann-Whitney
Hologic Panther	21.0 n = 25	25.8 n = 445	n = 470	$P=0.0190$ Mann-Whitney
Vaccine				
No vaccine	166 (77.9%)	3349 (90.5%)	3515 (89.8%)	$P<0.0001$
>7 days past 1st vaccine	5 (2.3%)	138 (3.7%)	143 (3.7%)	Chi-square
>14 days past 2nd vaccine	42 (19.7%)	213 (5.8%)	255 (6.5%)	

Data include 3913 unique patients with high-quality sequence results between March 15, 2021, and July 3, 2021.

BMI: body mass index; CI: confidence interval; ECMO: extracorporeal membrane oxygenation; LOS: length of stay

Table 1B. Summary of pertinent patient metadata for the 255 fully vaccinated patients

	Vaccinated	Not Vaccinated	Total	Statistical Analysis
Median PCR Cycle Threshold				
Abbott Alinity	35.18 n = 123	25.12 n = 1297	n = 1420	$P<0.0001$ Mann-Whitney
Hologic Panther	35.5 n = 33	25.5 n = 437	n = 470	$P=0.0029$ Mann-Whitney
Admission Data				

Admitted	110 (43.1%)	2019 (55.2%)	2129 (54.4%)	P=0.0002
Not Admitted	145 (56.9%)	1639 (44.8%)	1784 (45.6%)	Fisher's exact test
				Odds Ratio: 0.616 (95% CI 0.478 to 0.794)
Delta Variant				
	Delta Variant	Other Variants	Total	
No. (%) with data	42 (16.5%)	213 (83.5%)	255	
Cancer Patient				
Yes	8 (19.0%)	26 (12.2%)	34 (13.3%)	P=0.2236
No	34 (81.0%)	187 (87.8%)	221 (86.7%)	Fisher's exact test
				Odds Ratio: 1.692 (95% CI 0.7369 to 4.057)
Admission Data				
Admitted	21 (50.0%)	89 (41.8%)	110 (43.1%)	P=0.3944
Not Admitted	21 (50.0%)	124 (58.2%)	145 (56.9%)	Fisher's exact test
				Odds Ratio: 1.393 (95% CI 0.733 to 2.648)